Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — H1 2020 Earnings Presentation
21 slides from Elixinol Wellness's earnings presentation, Aug 31, 2020
Slide 1: H1 FY2020 Results Presentation
H1 FY2020 Results Presentation For personal use only 31 August 2020 ASX:EXL | OTC:ELLXF Kind of Amazing 1
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation contains To the maximum extent permitted by law, no This presentation contains Such forward‐looking statements are based on summary information responsibility for any loss arising in any way from certain forward‐looking statements with numerous abou
Slide 3: Our Vision and Mission
H1 FY2020 Results Presentation OUR VISION: For personal use only Building a global, consumer led and Elixinol-branded CBD nutraceuticals business. OUR MISSION Making a positive contribution to people’s health & wellness and the planet through the power of hemp products. Kind of Amazing 3
Slide 4: What we stand for: Must Wins and Values
H1 FY2020 Results Presentation What we stand for.... For personal use only MUST WINS VALUES Heritage Global Knowledge Quality & Transparency Compliance Focus Champions in Our global footprint Our products are We maintain a strict hemp for delivers highest quality science & evidence compliance focus
Slide 5: H1 FY2020 Financial Results
FY2019 CANNABIS WHO RESULTS BUSINESS FINANCIAL H1 FY2020 FINANCIAL RESULTS DEFINITION WE ARE OVERVIEW OVERVIEW RESULTS OUTLOOK Q+A For personal use only Kind of Amazing 5
Slide 6: Key Highlights for H1 FY2020
H1 FY2020 Results Presentation Key Highlights for H1 FY2020 For personal use only Elixinol aggressively repositioned in H1 FY2020; operations have been reshaped to improve efficiency and effectiveness , the brand has been relaunched, and an upskilled leadership team was established whilst securing E
Slide 7: Key Highlights for H1 FY2020
H1 FY2020 Results Presentation Key Highlights for H1 FY2020 For personal use only Continued focus on branded consumer goods model to premiumise margins Revenue channel mix 31 December year end • H1 FY2020 unaudited revenue from continuing operations of $7.9m, 9% down 54% ($17.1m in H1 FY2019) 22% 26
Slide 8: Financial Summary
H1 FY2020 Results Presentation Financial Summary For personal use only Continued focus on sales of Elixinol branded products Revenue • 54% decline H1 FY2020 vs H1 FY2019 driven by: ($m) H1 FY2020 H1 FY2019 • COVID-19 impacts led to challenging retail market conditions Revenue 7.9 17.1 • Termination
Slide 9: Cash Flow
H1 FY2020 Results Presentation Cash Flow For personal use only 47% reduction in quarterly operating cash outflows Operating activities ($m) H1 FY2020 H1 FY2019 • Significant focus to improve cashflows Operating activities (15.2) (28.9) • 47% reduction in quarterly operating cash outflows from $17.6m
Slide 10: Financial Position
H1 FY2020 Results Presentation Financial Position For personal use only $16.8m cash, virtually no debt, usable inventory to support revenue growth for more than 12 months ($m) 30 Jun 2020 31 Dec 2019 Current assets Cash and cash equivalents 16.8 20.2 Current assets Trade & other receivables 1.3 1.5
Slide 11: Enhancing Our Model: Thriving in a V.U.C.A. Environment
H1 FY2020 Results Presentation ENHANCING OUR MODEL For personal use only Thriving in a V.U.C.A. Environment Improve Cash Flow Enhance Margins Simplify Revenue Growth Markets Global E-Commerce (Q2 vs Q1) Making it easier to do business with EU/UK: 39% growth Q2 FY’20 (vs Q1 FY'20) 28% of global sales
Slide 12: Strategy and Outlook
STRATEGY AND OUTLOOK For personal use only Kind of Amazing 12 12
Slide 13: The New Elixinol
H1 FY2020 Results Presentation NEW SPORTS CAMPAIGN THE NEW ELIXINOL For personal use only The NEW Elixinol range is ideally positioned to participate in the the global growth of nutraceutical wellness products. CBD blended capsules, proven health benefits 13 Daily Balance Immune Booster Happy Belly
Slide 14: Skincare Launch
H1 FY2020 Results Presentation SKINCARE LAUNCH For personal use only Our new elixinolSkin range opens up new growth channels with fewer regulatory constraints. Boots Ireland secured as first-to-market launch partner. 14 Vegan Cruelty Free Natural 14 14 14 14
Slide 15: Market Outlook & Regulatory Environment
H1 FY2020 Results Presentation Market Outlook & Regulatory Environment For personal use only Strong market opportunity across US and Europe Regulation differs across key markets According to Brightfield US regulatory framework uncertain: Group: • Highly competitive and under-regulated market. In mid
Slide 16: Global Growth
H1 FY2020 Results Presentation GLOBAL GROWTH For personal use only Our established global reach offers diversified opportunities and diversifies risk. ASIA • Most established and leading brand in Japan • Licensing agreement with Elixinol Japan. Supply of HFA products. AMERICAS • HFA testing route to
Slide 17: Hemp Foods Australia
H1 FY2020 Results Presentation HEMP FOODS AUSTRALIA For personal use only Consistent growth with improved margins and leaner operations E-Commerce Revenue Jan-20 Feb-20 Mar-20 Apr-20 May-20 Jun-20 Jul-20 Kind of Amazing 17
Slide 18: Agile + Responsible COVID Response
H1 FY2020 Results Presentation AGILE + RESPONSIBLE COVID RESPONSE For personal use only We harness the COVID-19 necessities to become a better business Amplify CBD Safeguarding business Channel Shift to E- Responsible capital wellness benefits continuity commerce, TV management shopping & pharmacy •
Slide 19: July Performance & Outlook
H1 FY2020 Results Presentation July Performance & Outlook For personal use only With a completely new brand, new leadership, a reduced cost base and a stabilised US business, we are now looking forward to our European operations contributing to an improved H2 outlook on the back of some notable brea
Slide 20: Takeaways
H1 FY2020 Results Presentation Takeaways For personal use only Elixinol Trusted & established Expanding positioned brand global presence within with fresh of Elixinol high growth nutraceuticals branded category offering products of global CBD Revenue growth from Skincare Virtually debt Elixinol bran
Slide 21: For More Information
For personal use only H1 FY2020 Results Presentation FOR MORE INFORMATION Investor relations and media please contact: Ron Dufficy Chief Financial Officer ron.dufficy@elixinolglobal.com Kind of Amazing 21